Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo C49 English + 你好 (nǐ hǎo) = limitless possibilities. Start learning Mandarin Chinese today—for free, forever. Amedeo C49 is completely free, for life. Next week: +49.

Breast Cancer

Free Subscription 13.10.2025 1 Am J Clin Pathol 2 Am J Surg 1 Ann Oncol 5 Ann Surg Oncol 2 BMC Cancer 1 Br J Cancer 1 Breast Cancer 2 Breast Cancer (Dove Med Press) 4 Breast Cancer Res 3 Breast J 2 Cancer 1 Cancer Chemother Pharmacol 1 Carcinogenesis 3 Clin Breast Cancer 1 Clin Cancer Res 1 Eur J Surg Oncol 1 Eur Radiol 1 Gene 1 Int J Oncol 1 J Clin Oncol 1 J Natl Cancer Inst 3 J Surg Oncol 2 Lancet Oncol 4 PLoS One 1 Proc Natl Acad Sci U S A 1 Radiology 2 Radiother Oncol

Retrieve available abstracts of this week’s articles: HTML format

Single Articles

Am J Clin Pathol

1. CORBIN HN, Neyaz A, Jones TE, Clark BZ, et al
   PRAME immunohistochemistry distinguishes breast secondary angiosarcoma from benign and atypical vascular lesions of the breast.
   Am J Clin Pathol. 2025;164:600-607.
   PubMed         Abstract available
   
   

   
   Am J Surg

2. CHUA PX, Soh SH, Ng QX, Zhou KX, et al
   What matters most? Understanding patient preferences in breast cancer treatment: A systematic review of discrete choice experiments.
   Am J Surg. 2025;250:116642.
   PubMed         Abstract available
   
   
3. LAL T, Hoehn RS, Montero AJ, Amin AL, et al
   Deconstructing racial disparities in timely treatment of triple-negative breast cancer: A causal mediation analysis.
   Am J Surg. 2025;250:116651.
   PubMed         Abstract available
   
   

   
   Ann Oncol

4. BURSTEIN HJ, Curigliano G, Gnant M, Loibl S, et al
   Tailoring Treatment to Cancer Risk and Patient Preference: The 2025 St Gallen International Breast Cancer Consensus Statement on Individualizing Therapy for Patients With Early Breast Cancer.
   Ann Oncol. 2025 Oct 8:S0923-7534(25)04718-0. doi: 10.1016/j.annonc.2025.
   PubMed         Abstract available
   
   

   
   Ann Surg Oncol

5. HUANG SY, Murray M, Rubio A, Okoro N, et al
   ASO Visual Abstract: Impact of Screening Mammography on Breast Cancer Outcomes in Women Aged 80 Years and Over.
   Ann Surg Oncol. 2025 Oct 10. doi: 10.1245/s10434-025-18488.
   PubMed        
   
   
6. MA D, Cao H, Wu J, Shang T, et al
   Analysis of the Current Status of De Novo Metastatic Breast Cancer Surgery in China and the USA: A Multicenter Real-World Study.
   Ann Surg Oncol. 2025 Oct 10. doi: 10.1245/s10434-025-18490.
   PubMed         Abstract available
   
   
7. COBB AN, Cortina CS
   ASO Author Reflections: Prognostic and Therapeutic Implications of Nodal Burden in HER2-Positive Breast Cancer.
   Ann Surg Oncol. 2025 Oct 10. doi: 10.1245/s10434-025-18525.
   PubMed        
   
   
8. CHAKRABORTY M, Sherwani Z, Narra LR, Yehia ZA, et al
   Reply to: "Preoperative Radiation Boost in Early Stage Breast Cancer: Effect on Re-excision and Complication Rates," by Sanli, Deniz et al.
   Ann Surg Oncol. 2025 Oct 8. doi: 10.1245/s10434-025-18489.
   PubMed        
   
   
9. WAGNER BD, Rubin J, Boe LA, Diwan R, et al
   ASO Visual Abstract: Are We Underestimating Breast Cancer-Related Lymphedema? The Impact of Diagnostic Thresholds and Compression Therapy.
   Ann Surg Oncol. 2025 Oct 8. doi: 10.1245/s10434-025-18509.
   PubMed        
   
   

   
   BMC Cancer

10. TAKADA K, Kashiwagi S, Nishikawa M, Kochi A, et al
    Differences in Sentinel lymph node biopsy outcomes and prognosis between HER2-low and HER2-zero breast cancer.
    BMC Cancer. 2025;25:1518.
    PubMed         Abstract available
    
    
11. LIU Y, Ren T, Chen X, He Q, et al
    Comparative efficacy and safety of CDK4/6 inhibitors combined with endocrine therapy in HR+/HR2- patients with advanced or metastatic breast cancer: a systematic review and network meta-analysis.
    BMC Cancer. 2025;25:1535.
    PubMed        
    
    

    
    Br J Cancer

12. CHEN X, Cao L, Feng M, Shuai Q, et al
    Breast cancer cell-derived adrenomedullin confers cancer-associated adipose remodeling through the cAMP/Creb1/Zeb1 axis.
    Br J Cancer. 2025 Oct 6. doi: 10.1038/s41416-025-03219.
    PubMed         Abstract available
    
    

    
    Breast Cancer

13. REZAEI MH, Meymandi MS, Moslemizadeh A, Madadizadeh E, et al
    Correction: The therapeutic potential of high-intensity interval training in a breast cancer model: focus on the Hippo signaling pathway.
    Breast Cancer. 2025 Oct 10. doi: 10.1007/s12282-025-01790.
    PubMed        
    
    

    
    Breast Cancer (Dove Med Press)

14. AGELIDIS A, Ter-Zakarian A, Jaloudi M
    Triple-Negative Breast Cancer on the Rise: Breakthroughs and Beyond [Response to Letter].
    Breast Cancer (Dove Med Press). 2025;17:877-881.
    PubMed        
    
    
15. FAN Y, Jin Y, Tian C, Zhang Y, et al
    Development and Validation of Machine Learning Models in Predicting Prognosis of Breast Cancer Patients with Lymph Nodes Metastasis Following Neoadjuvant Chemotherapy.
    Breast Cancer (Dove Med Press). 2025;17:883-896.
    PubMed         Abstract available
    
    

    
    Breast Cancer Res

16. CHEN XY, Wang Y, Li DR, Liu BQ, et al
    Dietary index for gut microbiota, genetic risk, and incidence of breast cancer: a prospective study.
    Breast Cancer Res. 2025;27:175.
    PubMed         Abstract available
    
    
17. SHEN J, Liu Y, Liu A, Gu X, et al
    Artificial intelligence-assisted ultrasound screening for breast cancer in China: a prospective, clustered, controlled, population-based study.
    Breast Cancer Res. 2025;27:173.
    PubMed         Abstract available
    
    
18. MARTIN-BEJARANO P, Sanchez-Tapia EM, Jessica P, Martin-Gomez T, et al
    Functional characterization of BRCA1 variants of unknown significance using homologous recombination repair assays.
    Breast Cancer Res. 2025;27:174.
    PubMed         Abstract available
    
    
19. AL DLALI M, Al Amri B, Al Zeheimi N, Al Busaidi R, et al
    Genomic landscape of cancer driver genes in Omani breast cancers: a pilot study.
    Breast Cancer Res. 2025;27:172.
    PubMed         Abstract available
    
    

    
    Breast J

20. HASHMI AA, Wahid N, Mudassir G, Irfan M, et al
    Programmed Death Ligand 1 (PDL1) Expression in Neoadjuvant Triple-Negative Breast Cancer: Association With Chemotherapy Response and Residual Cancer Burden.
    Breast J. 2025;2025:8856567.
    PubMed         Abstract available
    
    
21. NELSON N, Den J, Weiser R, Digbeu B, et al
    The Era "or Error" of Second Localization Procedures.
    Breast J. 2025;2025:6391905.
    PubMed         Abstract available
    
    
22. BROWN N, Muirhead F
    Life Postdiagnosis: Female Adult Breast Cancer Survivors' Experience With Physical Activity-A Qualitative Systematic Review.
    Breast J. 2025;2025:6926093.
    PubMed         Abstract available
    
    

    
    Cancer

23. BOWER JE, Radin A, Ganz PA, Irwin MR, et al
    Inflammation and dimensions of fatigue in women with early stage breast cancer: A longitudinal examination.
    Cancer. 2025;131:e70038.
    PubMed         Abstract available
    
    
24. GIAQUINTO AN, Freedman RA, Newman LA, Jemal A, et al
    Lobular breast cancer statistics, 2025.
    Cancer. 2025;131:e70061.
    PubMed         Abstract available
    
    

    
    Cancer Chemother Pharmacol

25. PIENIAZEK M, Kubeczko M, Las-Jankowska M, Polakiewicz-Gilowska A, et al
    Sacituzumab Govitecan initial dose reduction in polish patients with metastatic triple-negative breast cancer: impact on efficacy and safety.
    Cancer Chemother Pharmacol. 2025;95:97.
    PubMed         Abstract available
    
    

    
    Carcinogenesis

26. YADAV R, Goel S, Kumari L, Dahiya D, et al
    Expression profile of Claudins 3, 4, and 7 in breast tumors and its correlation with clinicopathological features.
    Carcinogenesis. 2025;46:bgaf049.
    PubMed         Abstract available
    
    

    
    Clin Breast Cancer

27. OU X, Shi F, Zhao Y, Zhou Q, et al
    Novel Multi-Biomarker Nomogram Combining CD155/CD226/TIGIT/CD96 Immune Checkpoint Axis for Postoperative Survival Prediction in Breast Cancer.
    Clin Breast Cancer. 2025 Sep 17:S1526-8209(25)00272.
    PubMed         Abstract available
    
    
28. MORADPANAH S, Forouzin S, Samadi Nasab F, Amirlatifi S, et al
    The Unseen Enemies: Harnessing the Role of Neutrophil Extracellular Traps in Breast Cancer Progression, Immune Evasion, and Treatment Resistance.
    Clin Breast Cancer. 2025 Sep 12:S1526-8209(25)00273.
    PubMed         Abstract available
    
    
29. MAHIOU K, Bonneau C, Coutant C, Martin AL, et al
    Effect of Breast Surgery on Quality of Life in BRCA Mutation Carriers With Invasive Breast Cancer: A CANTO Database Study.
    Clin Breast Cancer. 2025 Sep 4:S1526-8209(25)00251.
    PubMed         Abstract available
    
    

    
    Clin Cancer Res

30. LIU R, Wang X, Branigan TB, Griffin D, et al
    BET bromodomain inhibition reverses CDK4/6 inhibitor resistance in estrogen receptor-positive breast cancer via induction of miR-34a-5p.
    Clin Cancer Res. 2025 Oct 7. doi: 10.1158/1078-0432.CCR-25-1406.
    PubMed         Abstract available
    
    

    
    Eur J Surg Oncol

31. CHONG K, Azmy I, Al-Shurbasi N, Hollywood C, et al
    Enhancing compliance and decision-making in breast cancer care for older adults: Optimising the NABCOP fitness assessment form.
    Eur J Surg Oncol. 2025;51:110475.
    PubMed         Abstract available
    
    

    
    Eur Radiol

32. SARDANELLI F, Scaperrotta G
    Artificial intelligence for breast cancer prevention: the vision ahead.
    Eur Radiol. 2025 Oct 8. doi: 10.1007/s00330-025-12036.
    PubMed         Abstract available
    
    

    
    Gene

33. SAFAN MA, Salem WM, Mekhail Y, Abdelfattah MM, et al
    Association of adiponectin and fat mass and obesity genetic variants with breast cancer risk in Egyptian females.
    Gene. 2025;971:149808.
    PubMed         Abstract available
    
    

    
    Int J Oncol

34. GELSOMINO L, Del Console P, Murfuni MS, Gaspari M, et al
    Adipocyte?derived extracellular vesicles sustain mitochondrial metabolism in breast cancer cells: New insights into the cross?talk between cancer cells and the tumor microenvironment.
    Int J Oncol. 2025;67:100.
    PubMed         Abstract available
    
    

    
    J Clin Oncol

35. BIDARD FC, Gessain G, Bachelot T, Frechin L, et al
    Erratum: Identifying Patients With Low Relapse Rate Despite High-Risk Estrogen Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Early Breast Cancer: Development and Validation of a Clinicopathologic Assay.
    J Clin Oncol. 2025 Oct 7:JCO2502272. doi: 10.1200/JCO-25-02272.
    PubMed        
    
    

    
    J Natl Cancer Inst

36. NGUYEN THT, Jeon S, Yoon J, Park B, et al
    Independent associations between obesity, glucose metabolism, and breast cancer risk through unrelated pathways.
    J Natl Cancer Inst. 2025 Oct 8:djaf287. doi: 10.1093.
    PubMed         Abstract available
    
    

    
    J Surg Oncol

37. WANG X, Shao Z, Zhu H, Zhang Q, et al
    Evolving Trends in Postmastectomy Breast Reconstruction With Autologous Tissues: A Large-Scale, 24-Year Retrospective Study in China.
    J Surg Oncol. 2025;132:845-852.
    PubMed         Abstract available
    
    
38. KIM M, Gilliland JL, Jiang CZ, Parnes MF, et al
    Sexual Health in Postmastectomy Breast Reconstruction Patients and Value of an Intervention: A Qualitative Study.
    J Surg Oncol. 2025;132:825-835.
    PubMed         Abstract available
    
    
39. ALTUNDAG K
    Liquid Biopsy in Metastatic Breast Cancer: Adoption Lags Despite Growing Evidence.
    J Surg Oncol. 2025 Oct 10. doi: 10.1002/jso.70107.
    PubMed        
    
    

    
    Lancet Oncol

40. SAVAS P, Loi S
    Whole-genome sequencing in breast cancer: is it ready for clinical application?
    Lancet Oncol. 2025 Oct 7:S1470-2045(25)00428.
    PubMed        
    
    
41. BLACK D, Davies HR, Koh GCC, Chmelova L, et al
    Clinical potential of whole-genome data linked to mortality statistics in patients with breast cancer in the UK: a retrospective analysis.
    Lancet Oncol. 2025 Oct 7:S1470-2045(25)00400.
    PubMed         Abstract available
    
    

    
    PLoS One

42. ADISU MA, Habtie TE, Kitaw TA, Gessesse AD, et al
    The rising burden of female cancer in Ethiopia (2000-2021) and projections to 2040: Insights from the global burden of disease study.
    PLoS One. 2025;20:e0333787.
    PubMed         Abstract available
    
    
43. TANG P, Zhang Q, Meng LC, Chen M, et al
    Predicting the axillary lymph node tumor burden in breast cancer patients using ultrasonic radiomics nomogram model.
    PLoS One. 2025;20:e0333172.
    PubMed         Abstract available
    
    
44. SAKAI Y, Kobayashi A, Akata M, Tojo K, et al
    Effects of anesthetic management on persistent pain after breast cancer surgery.
    PLoS One. 2025;20:e0333878.
    PubMed         Abstract available
    
    
45. RAMADAN MM, Alkhatabi HA, Aboalola D, Alaa S, et al
    Burden, and trends of breast cancer along with attributable risk factors in Gulf Cooperation Council countries from 1990 to 2019 and its projections.
    PLoS One. 2025;20:e0331198.
    PubMed         Abstract available
    
    

    
    Proc Natl Acad Sci U S A

46. BERGMAN RE, Keeton CI, Sinha IR, Ling JP, et al
    Distinct and convergent effects of SF3B1 mutations in human breast cancer.
    Proc Natl Acad Sci U S A. 2025;122:e2505374122.
    PubMed         Abstract available
    
    

    
    Radiology

47. PARK VY, Choi JS, Han K, Nahm S, et al
    Imaging Features and Diagnostic Performance of US in Nonmass Lesions with Varying Clinical Indications.
    Radiology. 2025;317:e243398.
    PubMed         Abstract available
    
    

    
    Radiother Oncol

48. BELARDO A, Dimayuga KB, Perna L, Fodor A, et al
    Density and volume of cardiac calcifications detected on planning CT predicts cardiotoxicity after hypo-fractionated whole breast Radiotherapy.
    Radiother Oncol. 2025;211:111098.
    PubMed         Abstract available
    
    
49. NG S, Kilburn LS, Kirby AM, Griffin C, et al
    Five-year trends and baseline predictors of patient-reported adverse events following breast radiotherapy with a boost in the IMPORT HIGH phase III randomised controlled trial.
    Radiother Oncol. 2025;211:111056.
    PubMed         Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Breast Cancer is free of charge.